All In Biotech

Drug Trial Radar · NCT07694089

Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas

A Randomized Trial of Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Aug 1, 2029

Study completion Aug 1, 2029

Sponsor

Lead sponsor
Akshitkumar MIstryAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cantex Pharmaceuticals Inc.; James Graham Brown Cancer Center
First posted
Jul 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn whether two alternatives to standard steroid treatment can safely control swelling around a brain tumor after surgery. The study will compare three approaches by placing participants in one of three study groups: standard dexamethasone (a steroid), no routine steroid treatment, and azeliragon, a study drug that may reduce brain swelling through a different pathway. Researchers want to determine whether these alternatives can control swelling while reducing some of the side effects associated with steroid use. Participants in this study will be randomly assigned to one of three study groups. Participants will undergo their planned brain tumor surgery and receive the treatment assigned to their group. Study procedures are the same as their routine care and include physical and neurological examinations, blood tests, MRI scans, review of medical records, and collection of tumor tissue removed during surgery (optional). Most study visits will occur during routine medical care. Participants will be followed for approximately 24 months after surgery.

Conditions

  • High-grade Gliomas (HGG)

Interventions

  • DexamethasoneDrug

    Potent FDA-approved corticosteroid

  • AzeliragonDrug

    orally bioavailable inhibitor of the receptor for advanced glycation endproducts (RAGE)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in peritumoral edema between the preoperative and postoperative periodTime frame: before the start of adjuvant chemo radiation (up to 6 weeks)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • UofL Health Brown Cancer Center; University of Louisville Hospital

    Louisville, Kentucky

  • UofL Health Jewish Hospital

    Louisville, Kentucky

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.